Literature DB >> 28670076

Acute exacerbation of myasthenia gravis with topical imiquimod use.

Saadeddine Saad1, Bobbak Mansouri1, Chad Housewright1.   

Abstract

Imiquimod activates the immune system when applied to a local area. We report a patient with a history of well-controlled myasthenia gravis who was prescribed imiquimod for lentigo maligna. Treatment was halted after 2 weeks when the patient reported itching and irritating sensations in his throat, consistent with previous myasthenia exacerbations. The symptoms improved once imiquimod use was discontinued. We advise clinicians to be cautious when prescribing imiquimod to a patient with a history of myasthenia gravis.

Entities:  

Year:  2017        PMID: 28670076      PMCID: PMC5468034          DOI: 10.1080/08998280.2017.11929637

Source DB:  PubMed          Journal:  Proc (Bayl Univ Med Cent)        ISSN: 0899-8280


  4 in total

Review 1.  Imiquimod: a review of off-label clinical applications.

Authors:  Consuelo V David; Hong Nguyen; Gary Goldenberg
Journal:  J Drugs Dermatol       Date:  2011-11       Impact factor: 2.114

2.  Exacerbation of myasthenia gravis during imiquimod treatment.

Authors:  Christopher M Wolfe; Nicole Tafuri; Keith Hatfield
Journal:  J Drugs Dermatol       Date:  2007-07       Impact factor: 2.114

Review 3.  Imiquimod: mode of action.

Authors:  M P Schön; M Schön
Journal:  Br J Dermatol       Date:  2007-12       Impact factor: 9.302

Review 4.  Myasthenia Gravis.

Authors:  Kelly G Gwathmey; Ted M Burns
Journal:  Semin Neurol       Date:  2015-10-06       Impact factor: 3.420

  4 in total
  1 in total

Review 1.  Management of keratinocyte carcinoma - Special considerations in the elderly.

Authors:  Alison Bailey; Brooke Vasicek; Joy Tao; Monica Janeczek; Andia Mitri; Rebecca Tung
Journal:  Int J Womens Dermatol       Date:  2019-05-18
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.